Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
. Milestone payments up to commercial launch are $26.5m, including $5m on grant of IND by the FDA (anticipated in late 2023). Total milestones of $160.5m are payable to the Company in relation to the first neurodevelopmental disorder indication under the license. Royalties payable to Evgen on sales are in the low to medium double-digit range in all scenarios, including on-licensing by Stalicla and use of SFX-01 in further licensed indications.
Oh for goodness sake, couldn’t get a buy quote earlier so took the dog out for a walk hoping I might come back and be able to buy in a bit cheaper and it’s now broken 6p.
I will invest a bit here when the price drops as we have a gap of one year here. Still really mainly a one drug company.
For me on AIM watch out for Valirx as 201 should be done soon but it has so much more with an evolving preclinical pipeline which is worth 10s millions once in SPV. The RNS shows investing early is the way forward rather than buying up 80%. Interesting times for biotechs GL all.
Must be happy now ..
Let’s see if we get another TR-1
Boom!
25283 shares kept only for an hour....£40 for his or hers lunch...cant believe some short termers
25283 shares kept only for an hour....£40 for his or hers lunch...cant believe some short termers
300% from 3p is 12p not 15p. So from 5.2p its about 135% to 12p.
They’ve secured $160M for the lead asset just for Neurodevelopmental & Schizophrenia from this Swiss Company.
Rights for ALL OTHER INDICATIONS belong to EVGEN.
Look at what else our lead asset is doing!!!!!
If not today, very likely this week.
Sometimes companies release "big" news and shares initially surge only for investors to find underneath the surface, the news wasn't all that significant.
This announcement is the exact opposite. This is genuinely big news with lots of supporting detail and hard numbers yet the share is so below the radar, the SP has been very slow to react. I honestly thought it would open up more than 100% and was amazed that it didn't.
The management team comprises devoted and highly respected scientists
So exciting!
All IMHO DYOR
Happy
Agreed the Rns points towards 10p plus
10p + today?
You believe that this should be a 300% RNS? If so still 200% to go then, I’ve taken some at 5.23 so by your view I should make 200% from that but in price. Fingers crossed!
5.2 IG. At lot of interest. Being funded for a couple years is key
Worth a punt
Pop in the bottom draw x
When Jim. Today or tomorrow cheers.
My personal strategy will be to hold through 2023. The pipelines of studies is excellent and there are some very exciting ongoing collaborations e.g. University of Michigan.
It feels like Sulforadex SFX-01, after the early setbacks years ago, is finally starting to realise its potential, which is vast. It is hugely significant to attract active commercial interest (e.g Stalicla and Juvescience) and the scientific validation of academic peers (e.g. University of Michigan).
Of course we still need to progress to clinical trials but the studies in oncology (colorectal cancer, glioblastoma, breast cancer) speak to the great potential and the social value of this work.
I was on the cusp of buying before today's unexpected announcement for a completely new area (autism, schizophrenia) so it's a great bonus.
We should start getting sizeable Juvescience payments by late 2023 so the future looks very bright indeed.
All IMHO DYOR
Happy
Imm is goin to be better than this , do your research
Nt ask for even a few hundred.
Reading the news again and researching this is a 300% RNS really.
About to blow the bloody doors off
5p bid
5p paid
There 5 can we break thru
4.87 paid
Teasing the sellers , should rerate towards 10p plus ...
I remember when these were 20p. RNS like this are very rare. Should be triple this Imo.